Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02981342
Registration number
NCT02981342
Ethics application status
Date submitted
1/12/2016
Date registered
5/12/2016
Date last updated
20/11/2019
Titles & IDs
Public title
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Query!
Scientific title
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Query!
Secondary ID [1]
0
0
I3Y-MC-JPCJ
Query!
Secondary ID [2]
0
0
16342
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pancreatic Ductal Adenocarcinoma
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Abemaciclib
Treatment: Drugs - LY3023414
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Capecitabine
Experimental: Abemaciclib - Abemaciclib given orally.
Experimental: Abemaciclib + LY3023414 - Abemaciclib given orally and LY3023414 given orally.
Experimental: Standard of Care (Gemcitabine or Capecitabine) - Gemcitabine given intravenously (IV) OR capecitabine given orally.
Treatment: Drugs: Abemaciclib
Administered orally
Treatment: Drugs: LY3023414
Administered orally
Treatment: Drugs: Gemcitabine
Administered IV
Treatment: Drugs: Capecitabine
Administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
Query!
Assessment method [1]
0
0
Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Query!
Timepoint [1]
0
0
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Query!
Primary outcome [2]
0
0
Stage 2: Progression Free Survival (PFS)
Query!
Assessment method [2]
0
0
PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.
Query!
Timepoint [2]
0
0
Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)
Query!
Secondary outcome [1]
0
0
Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR
Query!
Assessment method [1]
0
0
Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Query!
Timepoint [1]
0
0
Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months)
Query!
Secondary outcome [2]
0
0
Stage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20))
Query!
Assessment method [2]
0
0
Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).
Query!
Timepoint [2]
0
0
Cycle(C)1 Day(D)14: 0 hour(h),0.5h,1h,2h,4h,6h,8h post dose
Query!
Secondary outcome [3]
0
0
Stage 1: PK: Area Under the Curve (AUC) (AUC[Tau]) of LY3023414
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)
Query!
Secondary outcome [4]
0
0
Stage 1: PK: Maximum Concentration (Cmax) at Steady State of LY3023414
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)
Query!
Secondary outcome [5]
0
0
Stage 2: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Query!
Secondary outcome [6]
0
0
Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months
Query!
Assessment method [6]
0
0
Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD =6 months. CR is defined as the disappearance of all target and non-target lesions & no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Query!
Timepoint [6]
0
0
Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 6 Months)
Query!
Secondary outcome [7]
0
0
Stage 2: Duration of Response (DoR)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 6 Months)
Query!
Secondary outcome [8]
0
0
Stage 2: Overall Survival (OS)
Query!
Assessment method [8]
0
0
OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Query!
Timepoint [8]
0
0
Baseline to Death from Any Cause (Up to 10 Months)
Query!
Secondary outcome [9]
0
0
Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level
Query!
Assessment method [9]
0
0
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Query!
Timepoint [9]
0
0
Baseline, 6 Months
Query!
Secondary outcome [10]
0
0
Stage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
Query!
Assessment method [10]
0
0
mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours, and typical completion time for this instrument is less than 5 minutes.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Query!
Timepoint [10]
0
0
Baseline, 6 Months
Query!
Secondary outcome [11]
0
0
Stage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
Query!
Assessment method [11]
0
0
The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions:
Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent).
Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much)
Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much).
Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Query!
Timepoint [11]
0
0
Baseline, 6 Months
Query!
Secondary outcome [12]
0
0
Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414
Query!
Assessment method [12]
0
0
Mean steady state exposure was reported by trough pre-dose plasma concentrations.
Query!
Timepoint [12]
0
0
C2D1: 0h, C3D1: 0h, C4D1: 0h
Query!
Secondary outcome [13]
0
0
Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose
Query!
Assessment method [13]
0
0
Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.
Query!
Timepoint [13]
0
0
C1D1: 2h Post dose
Query!
Eligibility
Key inclusion criteria
- Histological or cytological diagnosis of ductal adenocarcinoma of the pancreas.
- Metastatic disease with documented disease progression following previous treatment
with at least one, but no more than 2 prior therapies, with one of the prior therapies
having been either gemcitabine-based or fluoropyrimidine-based therapy. Neoadjuvant
and/or adjuvant therapies for localized resectable or unresectable PDAC each count as
a line of therapy if multiagent chemotherapy regimens were administered (and
neoadjuvant regimen was different than adjuvant regimen) and if the participant
progressed with metastatic disease while taking or within 6 months of completion of
(neo)adjuvant therapy.
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participant for whom treatment with monotherapy chemotherapy such as gemcitabine or
capecitabine is a reasonable choice.
- Discontinued all prior treatment for cancer at least 14 days prior to initial dose of
study treatment.
- Adequate organ function.
- allow alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5x
upper limit of normal (ULN) if liver metastases.
- allow bilirubin up to 2.5 times ULN if elevation is not associated with other
signs of liver toxicity or can be explained by mechanical obstruction - requires
clinical research physician approval.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have a personal history of any of the following conditions: syncope of either
unexplained or cardiovascular etiology, ventricular arrhythmia (including but not
limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac
arrest. Exception: Participants with controlled atrial fibrillation for >30 days prior
to study treatment initiation are eligible.
- Have insulin-dependent diabetes mellitus. Participants with type 2 diabetes mellitus
are eligible if adequate control of blood glucose level is obtained by oral
anti-diabetics as documented by hemoglobin A1c (HbA1c) <7%.
- Have symptomatic central nervous system metastasis. Screening of asymptomatic
participants is not required for enrollment.
- Have had major surgery within 7 days prior to initiation of study drug to allow for
postoperative healing of the surgical wound and site(s).
- Have previously received treatment with any cyclin-dependent kinase (CDK) 4 and 6
inhibitor or phosphatidylinositol 3-kinase (PI3K) and/or mammalian target of rapamycin
(mTOR) inhibitor or have a known hypersensitivity to any component of the
investigational products in this study.
- Have a known hypersensitivity to investigator's choice of standard of care
(gemcitabine or capecitabine).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/01/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/11/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
106
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Blacktown
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
2010 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Connecticut
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Missouri
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New Hampshire
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Pennsylvania
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Tennessee
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Washington
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Wisconsin
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Brussels
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Edegem
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Leuven
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Wilrijk
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Lyon
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Paris
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Pessac
Query!
Country [16]
0
0
Israel
Query!
State/province [16]
0
0
Haifa
Query!
Country [17]
0
0
Israel
Query!
State/province [17]
0
0
Ramat Gan
Query!
Country [18]
0
0
Israel
Query!
State/province [18]
0
0
Tel Aviv
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Barcelona
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Hospitalet de Llobregat
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Madrid
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Malaga
Query!
Country [23]
0
0
Taiwan
Query!
State/province [23]
0
0
Tainan
Query!
Country [24]
0
0
Taiwan
Query!
State/province [24]
0
0
Taipei city
Query!
Country [25]
0
0
Taiwan
Query!
State/province [25]
0
0
Taipei
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in
combination with other drugs versus standard of care in participants with previously treated
metastatic pancreatic ductal adenocarcinoma (PDAC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02981342
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02981342
Download to PDF